Who Paid My Doc
Jefferey Ralph
Neuromuscular Medicine San Francisco, CA Medical Doctor
NPI 1073542676 CMS profile 422247
400 Parnassus Ave, San Francisco, CA 94143
General payments
$349
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$649
Through program year 2024, Jefferey Ralph of San Francisco, CA is reported in the CMS Open Payments database as having received $349 across 4 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $649 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 29th percentile of Neuromuscular Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $131 | 2 | |
| 2023 | General | $218 | 2 |
Beside peers
- Jefferey Ralph
- Neuromuscular Medicine median
- Middle half of Neuromuscular Medicine
- National median
In program year 2025, general payments to Jefferey Ralph were reported at $0. Among 188 Neuromuscular Medicine profiles paid that year, the median was $530 and the middle half received between $134 and $6,440.
Show as a table
| Year | Jefferey Ralph | Neuromuscular Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $356 | $114–$4,219 | $163 |
| 2020 | $0 | $287 | $72–$5,632 | $114 |
| 2021 | $0 | $193 | $73–$1,841 | $132 |
| 2022 | $0 | $362 | $109–$2,461 | $149 |
| 2023 | $218 | $411 | $119–$3,356 | $160 |
| 2024 | $131 | $394 | $122–$5,116 | $164 |
| 2025 | $0 | $530 | $134–$6,440 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 24 drugsPart D claims
970
Drug cost
$2,951,080
Branded share of claims
26.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Privigen Immun Glob G(Igg)/Pro/Iga 0-50 | Brand | 96 | $1,004,325 | |
| Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 | Brand | 67 | $804,691 | |
| Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 | Brand | 42 | $464,059 | |
| Panzyga Immun Glob G(Igg)-Ifas/Glycine | Brand | 16 | $456,294 | |
| Octagam Immun Globg(Igg)/Malt/Iga Ov50 | Brand | 12 | $183,657 | |
| Mycophenolate Mofetil | Generic | 35 | $8,791 | |
| Pyridostigmine Bromide | Generic | 79 | $7,519 | |
| Azathioprine | Generic | 21 | $3,396 | |
| Gabapentin | Generic | 110 | $3,300 | |
| Duloxetine Hcl | Generic | 110 | $3,155 |
The 10 drugs with the highest cost, of 24 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 27 billing codesPaid by Medicare
$85,374
Medicare patients
379
Services billed
1,013
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 70% | |
| Arthritis | 58% | |
| Diabetes | 28% | |
| Depression | 27% | |
| Ischemic heart disease | 26% | |
| Osteoporosis | 24% | |
| Chronic kidney disease | 19% | |
| Cancer | 18% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
4 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neuromuscular Medicine in California
Samir MacWan
Neuromuscular Medicine · Rancho Mirage, CA
Ali Habib
Neuromuscular Medicine · Orange, CA
Tahseen Mozaffar
Neuromuscular Medicine · Orange, CA
Jeffrey Rosenfeld
Neuromuscular Medicine · Fresno, CA
John Day
Neuromuscular Medicine · Stanford, CA
Marwa Kaisey
Neuromuscular Medicine · West Hollywood, CA
Related records
Neuromuscular Medicine in California
Practitioners in the same specialty and state, ranked by reported value.
All Neuromuscular Medicine
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.